Revvity
Company Snapshot
Company Overview
The PerkinElmer Life Sciences and Diagnostics Company, renamed during the second quarter of 2023 is a leading provider of health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development and diagnosis to cure. Revvity offers comprehensive solutions in reagents, consumables, assays, instruments, and software to various markets, including pharma, biotech, diagnostic labs, academia, and government agencies.
The company manages its business in two segments: Life Sciences and Diagnostics. Life Sciences provides products and services targeted towards life sciences customers. The Diagnostics segment is especially focused on reproductive health, immunodiagnostics, emerging market diagnostics and applied genomics. Revvity Omics offers genomic testing focused on rare inherited diseases, newborn screening, and hereditary cancers. The offered services support the full continuum of care from preconception and prenatal to neonatal, pediatrics, and adult.
Revvity Omics is a global laboratory network offering multi-OMIC clinical grade services for testing in cytogenetics, biochemical genetics (prenatal and postnatal), molecular genetics and immunodiagnostics. The laboratory network includes testing laboratories in the U.S., Sweden, India, China and the U.K.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- Life Sciences : Sales of instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services
- Diagnostics : Sales of instruments, solutions, consumables, reagents, and services
Applications/End User Industries
- Hospitals
- Medical Labs
- Clinicians
- Medical Research Professionals
- Research Institutions
- Pharmaceutical Companies
